CLINUVEL considers Nasdaq listing, ASX delisting

Key points

• Board considering Nasdaq listing and ASX delisting
• Shareholders to receive shares in the new Nasdaq-listed entity
• Operational headquarters to relocate to the United States
• Transaction subject to approvals

Full summary

Clinuvel Pharmaceuticals Ltd. announced that its Board of Directors is exploring a transaction to list all ordinary shares on the Nasdaq Stock Market and delist from the ASX. Under the proposed transaction, shareholders would receive shares in a new foreign holding company, New HoldCo, which would seek a Nasdaq listing. The transaction is subject to final Board approval, finalization of structure and documentation, and necessary shareholder and regulatory approvals. The company's operational headquarters will relocate to the United States from 1 January 2027. The proposed Nasdaq listing reflects the increasing importance of Clinuvel's operations in the United States, the largest global market in scientific innovation.